HAC(SH:600202) Zhi Tong Cai Jing·2025-11-21 09:48Core Viewpoint - The company plans to publicly transfer 40.00% equity stake in its subsidiary Harbin Fushanchuan Biotechnology Development Co., Ltd. at the Heilongjiang United Property Rights Exchange, with an estimated market value of RMB 953.14 million for the entire equity as of December 31, 2024 [1] Group 1 - The estimated value of the 40.00% equity stake held by the company in Fushanchuan is RMB 381.26 million, subject to final approval by the state-owned asset regulatory authority [1] - The minimum listing price for the equity transfer will not be less than the assessed value of RMB 381.26 million, in accordance with state asset supervision regulations [1] - The transfer of the equity stake is aimed at optimizing resource allocation and focusing on core industries, aligning with the company's development strategy and positioning [1] Group 2 - The equity transfer will not affect the company's existing main business and will not have a significant impact on the company's ongoing operations and overall development [1]